XBIT - XBiotech Forward P/S Multiple
XBiotech Inc. (XBIT) relies on a narrow development portfolio, making its resilience dependent on trial outcomes. Success is based on the confirmed efficacy of "human" antibodies and patent protection. A unique synthesis without side effects will allow the company to maintain pricing power. The expected P/S trend illustrates market expectations, with the metric settling at 597.60.
XBIT (xbiotech.com): analytical breakdowns and indicator data
- current price and projected stock value:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
XBIT - Net Financial Result|Expected Profit XBiotech Inc.|XBIT - Price to Earnings Multiple|Forward P/E Multiple XBiotech|XBIT - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio XBIT|XBIT - Operating income before deduction of amortization|Net earnings per share for the last 12 months XBiotech|XBIT - Earnings per share for the last 12 months|Quarterly EPS earnings growth xbiotech.com|XBIT - Earnings per share growth in current year|Earnings growth forecast for next year XBiotech Inc.
- revenue and sales details:
Analysis of all company metrics:XBiotech USA XBIT
XBiotech Inc. (XBIT) investments in a unique antibody platform and the retention of R&D specialists establish a foundation for future revenues, which are valued through the ratio of current market capitalization to projected revenue per share. An analysis of the expected price-to-sales ratio allows for the determination of asset overbought conditions, signaling to institutional investors the need to review capital concentration risks when the indicator reaches extreme values.
Key competitors
Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. - Price-to-Projected Revenue Ratio|RevMed - Forward P/S Multiple|Market Cap to Expected Sales Ratio Ascentage Pharma Corp AAPG|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio urogen.com (URGN)|Forward Price-to-Revenue Multiple BCAX|PSNL (Personalis Inc) - Price to Expected Revenue Ratio|Forward P/S Multiple ERAS|DCTH - Market Cap to Future Revenue Ratio|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|AURA - Forward Price-to-Revenue Multiple|Candel - Forward P/S Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|Actuate Therapeutics Inc - Forward Price to Sales|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|TuHURA (HURA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Protara Therapeutics, Inc. (TARA)|Fate Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX - Forward Price-to-Revenue Multiple|CSBR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio CEL-SCI Corporation CVM|OSTX (OS Therapies) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue RADX|ARTV (Artiva Biotherapeutics Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ANL|Forward P/S Multiple VERU|Market Cap to Expected Sales Ratio tempesttx.com|Xilio Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio RENB (Renovaro Biosciences)|Mural Bio - Forward P/S Multiple|Kairos Pharma Ltd (KAPA) - Forward Price-to-Revenue Multiple|OKUR: Forward P/S Multiple|CytoMed Therapeutics Limited (GDTC) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Curis Inc.|Market Cap to Projected Revenue APLM (Apollomics Corp)|Forward P/S Multiple THAR|Forward Price-to-Revenue Multiple advanbiomed.com ADVB|Forward P/S Multiple GNPX (Genprex, Inc.)|Calidi Biotherapeutics Inc. (CLDI) - Market Cap to Future Revenue Ratio|SBFM - Price-to-Projected Revenue Ratio|Forward Price to Sales XBIO (Xenetic Biosciences)|SLRX (Salarius) - Forward Price-to-Revenue Multiple|Kitov Pharma - Forward Price to Sales|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward Price-to-Revenue Multiple CKPT (Checkpoint Therapeutics, Inc.)|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|Forward Price to Sales IKNA|Notable Labs, Ltd. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viracta Therapeutics|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue NAYA|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
